Composition and production of pancreatic tumor related antigens
- 13 Downloads
Large numbers of specific and highly purified antibodies that react with tumor-associated antigens (TAAs) have been produced over the last decade as a result of the hybridoma technology that was developed during the previous decade. The availability of monoclonal antibodies (MAbs) rapidly led to studies of their clinical applicability. It has recently become apparent that further characterization of TAAs at the molecular level is needed before the MAbs, which react with TAAs, can have extensive use in the diagnosis and treatment of pancreatic cancer. The information that is currently available concerning the molecular composition and production of pancreatic TAAs is summarized in this presentation.
Key WordsPancreatic cancer tumor-associated antigens
Unable to display preview. Download preview PDF.
- 7.Pour PM, Tempero MM, Takasaki H, Uchida E, Takiyama Y, Burnett DA, and Steplewski Z. Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19–9 in pancreatic cancer cells in comparison with the patient’s blood group type. Cancer Res. 1988; 48: 5422–5426.PubMedGoogle Scholar
- 16.Chung YS, Ho JJL, Kim YS, Tanaka H, Nakata B, Hiura A, Motoyoshi H, Satake K, and Umeyama K. The detection of human pancreatic cancer-associated antigen in the serum of cancer patients. Cancer 1987; 1636–1643.Google Scholar
- 22.Ozawa S, Ueda M, Ando N, Abe O, and Shimizu N. Epidermal growth factor receptors in cancer tissues of esophagus, lung, pancreas, colorectum, breast and stomach. Jpn. J. Can. Res. 1988; 79: 1201–1207.Google Scholar
- 28.Kern HF, Zorr A, Theiss U, Bosslet K, Schorlemmer HV, Schulz G, and Sedlacek HH. Cell biology of human pancreatic adenocarcinoma: review of tumour markers. Cancer of the Bile Ducts and Pancreas Preece PE, Cushieri A, and Rosin RD, eds., WB Saunders, Philadelphia 1989.Google Scholar
- 29.Shetye J, Frodin JE, Christensson B, Grant C, Jacobsson B, Sundelius S, Sylven M, Biberfeld P, and Mellstedt H. Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A). Cancer Immunol. Immunother. 1988; 27: 154–162.PubMedCrossRefGoogle Scholar
- 32.Beretta E, Malesci A, Zerbi A, Mariani A, Carlucci M, Bonato C, Ferrari AM, and DiCarlo V. Serum CA 19–9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer 1987; 2428–2431.Google Scholar
- 33.Montz R, Klapdor R, Rothe B, and Heller M. Immunoscintigraphy and radioimmuno- therapy in patients with pancreatic carcinoma. Nucl. Med. 1986; 25: 239–244.Google Scholar
- 34.Centocor, Inc., Malvern, PA. A Phase II Study of Murine Monoclonal Antibody 17–1A in Patients with Advanced Adenocarcinoma of the Pancreas. Eastern Cooperative Oncology Group. (Est-PZ288). Suspended: April, 1989; unpublished data.Google Scholar